Meanwhile, the BSE Sensex was up 95.50 points, or 0.55% to 17,556.08.

On BSE, 39,183 shares were traded in the counter as against an average daily volume of 3.03 lakh shares in the past one quarter.

The stock hit a high of Rs 157 and a low of Rs 154.30 so far during the day. The stock had hit a 52-week high of Rs 239.40 on 16 December 2009 and a 52-week low of Rs 78.10 on 13 July 2009.

The mid-cap stock had underperformed the market over the past one month till 20 April 2010, declining 4.24% as compared to the Sensex's 0.67% fall. It had also underperformed the market in the past one quarter, falling 17.18% as compared to the Sensex's decline of 0.08%.

The company's equity capital is Rs 70.44 crore. Face value per share is Rs 10.

The company has secured tentative approval from the US Food & Drug Administration (US FDA) to market Modafinil tablets in multiple strengths. The drug is the generic version of Cephalon's Provigil tablets and used to treat depression.

Orchid Chemicals and Pharmaceuticals reported a higher net loss of Rs 16.86 crore in Q3 December 2009 compared with a net loss of Rs 6.31 crore in Q3 December 2008. Net sales rose 4.6% to Rs 308.84 crore in Q3 December 2009 over Q3 December 2008.